Distributed Technologies Research Simplifies Global Payments
11.12.2024 10:00:00 CET | Business Wire | Press release
Introduces Revolutionary B2B Payment Solutions
Distributed Technologies Research (DTR), a fintech company focused on simplifying global payments infrastructure, officially launched its technology platform today. DTR seamlessly bridges national payment systems around the world to make financial transactions efficient, secure and universally accessible.
Current payment networks suffer from inefficiencies – such as transfer costs, interchange fees, FX conversion charges, settlement delays and other opaque fees – that effectively act as an indirect tax on consumers worldwide. DTR’s innovative solutions mitigate these inequities with an adaptable, compliant and scalable payment systems architecture that is globally accessible to businesses of all sizes.
“Our team has spent several years studying the systemic barriers within traditional payment systems. The amalgamation of national payments systems with blockchain technologies has the potential to eliminate the hidden tax on consumers,” said Akshay Naheta, Founder & CEO of DTR.
DTR has unveiled AmalgamOS™, a state-of-the-art technology stack designed to streamline money transfers and merchant payments. Leveraging its proprietary International Orchestration Network (ION), AmalgamOS™ enhances financial connectivity and security for businesses worldwide. Currently live and trusted by numerous merchants and corporate clients, AmalgamOS™ enables instant fiat-to-fiat, fiat-to-stablecoin and stablecoin-to-fiat transactions in over 40 countries, with a roadmap into more than 100 countries in 2025.
Key Features of AmalgamOS™:
Enhanced Transaction Speed: Transactions settle in minutes, leveraging blockchains’ 24/7 operational capability.
Cost Efficiency: Reduced reliance on intermediaries drastically lowers transaction fees.
Global Reach: Currently operational for payouts in over 40 countries worldwide, with pay-in capabilities available across EU nations. The platform is consistently expanding, with new countries being added monthly to enhance global reach and accessibility.
Developer-Centric Design: Flexible API’s, easy-to-integrate widgets, comprehensive white-label solutions, and a merchant control panel provide extensive optionality through simple integrations.
DTR’s interdisciplinary team combines seasoned professionals from traditional finance, payment systems, blockchains and Web3 technology. “DTR is dedicated to its goal of redefining the payments ecosystem by fostering inclusivity and eliminating inefficiencies, benefitting millions of people worldwide. By leveraging blockchain technologies for transparency, security and instantaneous settlements, DTR is addressing the growing demand for efficient and scalable payments solutions,” said Naheta.
Stablecoin transaction volume reached $8.5 trillion(1) in the second quarter of 2024 alone, and the global cross-border payments market is projected to grow to $290 trillion by 2030 from $190 trillion in 2023(2). DTR is uniquely positioned to lead this global payment systems transformation.
About Distributed Technologies Research (DTR)
Distributed Technologies Research (DTR) is at the forefront of simplifying how businesses conduct secure and seamless money transfers globally. We connect disparate national payment networks to enable a worldwide, instantaneous payments ecosystem. Our proprietary AmalgamOS™ technology and International Orchestration Network (ION) provide next-generation payments infrastructure and solutions.
For more information, visit http://www.dtr.org/
About Akshay Naheta, Founder & CEO, DTR
Akshay Naheta founded DTR with a vision to simplify financial transactions through the creation of an advanced global payments infrastructure. He brings over 20 years of experience in finance and technology, with an intricate understanding of blockchains, financial markets and payment systems. Previously, he held senior executive roles at SoftBank Group, where he spearheaded numerous technology investments in industry leaders such as ARM, Auto1 and Nvidia.
Sources:
(1) a16z, State of Crypto Report 2024. https://tinyurl.com/yn9wwjzj
(2) FTX Intelligence, Cross-border payments market sizing data. https://tinyurl.com/bdr7nkdv
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210988080/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom